RxDoctor Payments DataLook up a doctor →

Paul Hahn, MD

Retina Specialist · Nanuet, NYNPI 1043360704

Payments from drug & device makers

$1,138,559in general payments, 2019–2025

Across 587 payments — averaging $1939.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$187K
  • Regeneron$185K
  • Novartis$154K
  • Boehringer Ingelheim International GmbH$122K
  • AstraZeneca$113K
  • Boehringer Ingelheim$112K
  • plus $265K from 24 others
$8,312in research payments, 2019–2025

Across 6 payments — averaging $1385.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$8K

What the payments were for

  • Consulting fees$162,56568%
  • Speaking & faculty fees$58,09524%
  • Travel & lodging$8,9334%
  • Food & beverage$8,2793%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,138,559 in reported general payments places this provider in the 95th percentile of 99 retina specialist providers in New York.

See all retina specialist providers in New York

Medicare billing

Part B allowed, 2024
$4,735,241
Medicare patients
972
Services billed
32,119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProlensaBromfenac Sodium22$7,680
Prednisolone Acetate116$4,811
Loteprednol Etabonate15$2,727
Bromfenac Sodium14$2,005
Ofloxacin38$418
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat16$199
Timolol Maleate17$169

Paid to pharmacies, not to this prescriber.

Other retina specialist in Nanuet

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →